|
KMID : 0360220090500071027
|
|
Journal of the Korean Ophthalmological Society
2009 Volume.50 No. 7 p.1027 ~ p.1034
|
|
|
Short-term Efficacy of Intravitreal Ranibizumab for Myopic Choroidal Neovascularization
|
|
Song Min-Hye
Roh Young-Jung
Kim Joon-Yong
|
|
|
Abstract
|
|
|
Purpose: To evaluate the effects of intravitreal ranibizumab in myopic choroidal neovascularization (CNV).
Methods: Patients who underwent intravitreal ranibizumab injection for myopic CNV, and were followed up more than 6 months, and their records were retrospectively investigated. The best corrected visual acuity, central macular thickness, and leak in fluorescein angiography were compared at baseline, and at 1, 3, and 6 months after injection.
Results: Twenty-one eyes of 18 patients were evaluated. The mean best corrected visual acuity (logMAR) was 1.23±0.65, 0.96± 0.40, 0.95±0.67, and 0.83±0.58 at baseline, 1, 3, and 6 months, respectively (p<0.001, p=0.006, p=0.001). The mean central macular thickness was 233.42±65.55 μm, 204.14±65.29 μm, and 157.76±71.45 μm at baseline, 3, and 6 months, respectively (p<0.001). In fluorescein angiography at 6 months after injection, regression was observed in 12 eyes, and fibrosis in 9 eyes.
Conclusions: Intravitreal ranibizumab injection for myopic CNV in Korean patients appeared to be effective, resulting in regression of lesion and improvement of visual acuity.
|
|
|
KEYWORD
|
|
|
Choroidal neovascularization, Pathologic myopia, Ranibizumab (Lucentisⓡ)
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|